A Decision Score provides prognostic discrimination for 10-year locoregional recurrence, with rising score associated with ...

Breast Cancer," Cleveland Clinic oncologist Tiffany Onger, MD, and host John Mangels continue their conversations on communicating effectively and empathetically with patients across the breast cancer ...

Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...

Please provide your email address to receive an email when new articles are posted on . A shorter radiation therapy regimen conferred similar outcomes as standard of care for women undergoing breast ...

SAN ANTONIO -- Postmastectomy chest-wall irradiation (CWI) for intermediate-risk breast cancer had no impact on long-term survival, results of a large British study showed. After a median follow-up of ...

Their recurrence rate, she said, is comparable to reported rates of disease recurrence after standard mastectomy. Furthermore, the procedure has several advantages over standard mastectomy. "Often, a ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an ...

The risk of isolated locoregional recurrence after initial treatment was 5.6% among young women diagnosed with breast cancer. This was lower than a previously reported 10-year rate of 8% among all ...

An open-label non–HLA-A*02 cohort showed a 0.7% annualized recurrence rate after primary immunization with GLSI-100, measured over an average 1.2 patient-years of exposure. Historical comparison to ...

Decision Support for Patients With Early-Stage Breast Cancer: Effects of an Interactive Breast Cancer CDROM on Treatment Decision, Satisfaction, and Quality of Life PURPOSE: Risk factors for local and ...